

No.18-101

November 27, 2018
Eisai Co., Ltd.

**EISAI TO PRESENT NEW RESEARCH ON ERIBULIN (HALAVEN®)
AT 41ST ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM**

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that the latest information on its in-house discovered and developed anticancer agent eribulin mesylate (halichondrin class microtubule dynamics inhibitor, product name: HALAVEN®, “eribulin”) will be presented during the 41st San Antonio Breast Cancer Symposium (SABCS). The symposium will be held from December 4 through 8, 2018, in San Antonio, Texas in the United States.

A total of four presentations will be given at this year’s SABCS, including the results of biomarker research from a Phase II clinical study evaluating eribulin in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A.’s (known as MSD outside the United States and Canada) anti-PD-1 therapy pembrolizumab (product name: KEYTRUDA®) for triple-negative metastatic breast cancer.

Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

Major presentations at this year’s SABCS:

Product	Abstract name and scheduled presentation date and time (local time)
Eribulin Poster no.: P5-12-02	<i>PTEN</i> alterations and tumor mutational burden (TMB) as potential predictors of resistance or response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC) Poster Session December 7 (Fri), 5:00-7:00PM
Eribulin Poster no.: P5-08-06	Differential effects of eribulin on key transcription factors snail and slug* Poster Session December 7 (Fri), 5:00-7:00PM
Eribulin Poster no.: P6-17-28	Outcomes of real-world use of eribulin plus trastuzumab for HER2-positive metastatic breast cancer Poster Session December 8 (Sat), 7:00-9:00AM
Eribulin Poster no.: OT2-07-05	A Phase III trial to compare eribulin mesylate + trastuzumab (H) + pertuzumab (P) with paclitaxel or docetaxel + HP for HER2-positive advanced or metastatic breast cancer (JBCRG-M06/EMERALD) Poster Session December 6 (Thu), 5:00-7:00PM

* Snail and slug: Major transcription factors that regulate epithelial-mesenchymal transition (transformation of cells involved in migration and infiltration of cancers)

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., U.S.A.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120